Immune Checkpoint Inhibitors in Advanced-Stage Non-small Cell Lung Cancer

Overview

Journal Turk Thorac J

Publisher Aves

Specialty Pulmonary Medicine

Date 2018 Feb 7

PMID 29404172

Citations 1

Authors

Seher Nazli Kazaz

Ilhan Oztop

Affiliations

Soon will be listed here.

Abstract

More than half of non-small cell lung cancer (NSCLC) patients are at an advanced stage at the time of diagnosis, and they have a poor prognosis. Systemic treatment is the basic treatment approach for advanced-stage NSCLC, and chemotherapy and targeted treatments are commonly used based on the molecular characteristics. Although targeted therapies have led to a significant level of improvement in terms of survival, the results are still unsatisfactory. However, considerable attention has been focused to the immunotherapy with recent positive results reported by studies on this field. In this context, a certain portion of clinical studies have shown dramatic results, and these have involved inhibitors developed particularly against the immune checkpoint protein programmed death receptor-1 and its ligand (programmed death ligand-1). This review aims to present the significance of immune checkpoint inhibitors in NSCLC and to summarize the findings of relevant contemporary clinical studies.

Citing Articles

Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer.

Shi L, Li Y, Yu T, Wang Z, Zhou C, Xing W Med Sci Monit. 2018; 24:8655-8668.

PMID: 30498189 PMC: 6284361. DOI: 10.12659/MSM.911125.

References

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Garajova I, Giovannetti E, Biasco G, Peters G . c-Met as a Target for Personalized Therapy. Transl Oncogenomics. 2015; 7(Suppl 1):13-31. PMC: 4659440. DOI: 10.4137/TOG.S30534. View

Abdel-Rahman O . Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. Crit Rev Oncol Hematol. 2016; 101:75-85. DOI: 10.1016/j.critrevonc.2016.03.007. View

Howington J, Blum M, Chang A, Balekian A, Murthy S . Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e278S-e313S. DOI: 10.1378/chest.12-2359. View

Passiglia F, Bronte G, Bazan V, Natoli C, Rizzo S, Galvano A . PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget. 2016; 7(15):19738-47. PMC: 4991415. DOI: 10.18632/oncotarget.7582. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Shukuya T, Carbone D . Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. J Thorac Oncol. 2016; 11(7):976-88. PMC: 7179759. DOI: 10.1016/j.jtho.2016.02.015. View

Parkin D, Bray F, Ferlay J, Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2):153-6. DOI: 10.1002/ijc.1440. View

Chen D, Irving B, Hodi F . Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012; 18(24):6580-7. DOI: 10.1158/1078-0432.CCR-12-1362. View

10.

Caparica R, de Castro Jr G, Gil-Bazo I, Caglevic C, Calogero R, Giallombardo M . BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?. Crit Rev Oncol Hematol. 2016; 101:32-9. DOI: 10.1016/j.critrevonc.2016.02.012. View

11.

Ribas A . Tumor immunotherapy directed at PD-1. N Engl J Med. 2012; 366(26):2517-9. DOI: 10.1056/NEJMe1205943. View

12.

Brahmer J . Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol. 2013; 31(8):1021-8. DOI: 10.1200/JCO.2012.45.8703. View

13.

Ettinger D, Akerley W, Borghaei H, Chang A, Cheney R, Chirieac L . Non-small cell lung cancer. J Natl Compr Canc Netw. 2012; 10(10):1236-71. DOI: 10.6004/jnccn.2012.0130. View

14.

Kempf E, Rousseau B, Besse B, Paz-Ares L . KRAS oncogene in lung cancer: focus on molecularly driven clinical trials. Eur Respir Rev. 2016; 25(139):71-6. PMC: 9487658. DOI: 10.1183/16000617.0071-2015. View

15.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

16.

Spranger S, Gajewski T . Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer. 2014; 1:16. PMC: 4019905. DOI: 10.1186/2051-1426-1-16. View

17.

Rizvi N, Mazieres J, Planchard D, Stinchcombe T, Dy G, Antonia S . Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015; 16(3):257-65. PMC: 5726228. DOI: 10.1016/S1470-2045(15)70054-9. View

18.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

19.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

20.

Collins L, Haines C, Perkel R, Enck R . Lung cancer: diagnosis and management. Am Fam Physician. 2007; 75(1):56-63. View